Literature DB >> 8562036

In vivo effects of thymostimulin treatment on monocyte polarization, dendritic cell clustering and serum p15E-like trans-membrane factors in operable head and neck squamous cell carcinoma patients.

J D Kerrebijn1, P J Simons, M Tas, A J Balm, H A Drexhage.   

Abstract

Head and neck squamous cell carcinoma patients have been characterized by impairments in their cell-mediated immune system, particularly by decreased chemotactic function of monocytes and impairments in the function of the monocyte-derived dendritic cells (viz, a decreased capability to form cell "clusters"). These impairments are thought to be due to immunosuppressive factors of low molecular mass released by tumor, the so-called p15E-like factors. These suppressive effects of p15-like factors can be neutralized in vitro by thymic peptides, such as thymostimulin (TP1). In a randomized double-blind, placebo-controlled multicenter trial in the Netherlands, 41 patients with operable head and neck squamous cell carcinomas (HNSCC) were treated for 10 days prior to surgery with intramuscular TP1 in one of three dosages (0.5 mg/kg; 1.0 mg/kg or 2.0 mg/kg body weight) or treated with placebo. Assessment of monocyte chemotaxis, the capability of dendritic cells to form clusters and the presence of p15E-like low-molecular-mass factors (LMMFs) in serum was performed before TP1 treatment and on the day of surgery. Findings demonstrated that TP1 in a dose of 1.0 mg/kg and 2.0 mg/kg resulted in normalization of impaired monocyte chemotactic capability. Although the cluster capability of dendritic cells after TP1 treatment improved, values only reached statistical significance for the 0.5 mg/kg group. Serum p15E-like LMMF levels were not affected by TP1 treatment in any of the patient groups. Contrary to expectations we found no correlation between elevated immunosuppressive LMMFs and defective monocyte chemotaxis or cluster capability of dendritic cells. We conclude that treatment with TP1 can improve monocyte chemotaxis in HNSCC patients but an effect on the production of p15E-like factors by carcinoma cells could not be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562036     DOI: 10.1007/bf00167311

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  39 in total

1.  Beneficial effects of the thymic hormone preparation thymostimulin in patients with defects in cell-mediated immunity and chronic purulent rhinosinusitis. A double-blind cross-over trial on improvements in monocyte polarization and clinical effects.

Authors:  M Tas; J A Leezenberg; H A Drexhage
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses.

Authors:  M Mitani; G J Cianciolo; R Snyderman; M Yasuda; R A Good; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

3.  Defective monocyte chemotaxis in patients with epidermoid tumors of the head and neck.

Authors:  A Güngör; S Yetgin; B Sözeri
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

4.  Monocyte responsiveness to chemotactic stimuli is a property of a subpopulation of cells that can respond to multiple chemoattractants.

Authors:  G J Cianciolo; R Snyderman
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

Review 5.  Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates.

Authors:  D R Vlock
Journal:  Hematol Oncol Clin North Am       Date:  1991-08       Impact factor: 3.722

6.  Impairment of monocyte functions in advanced head and neck cancer.

Authors:  O Garraud; A Faucher; E Legrand
Journal:  Immunol Lett       Date:  1988-07       Impact factor: 3.685

7.  Mononuclear phagocyte function in head and neck cancer: depression of murine macrophage accumulation by low molecular weight factors derived from head and neck carcinomas.

Authors:  F J Balm; B M von Blomberg-van deFlier; H A Drexhage; M de Haan-Meulman; G B Snow
Journal:  Laryngoscope       Date:  1984-02       Impact factor: 3.325

8.  Characterization of formylpeptide chemoattractant binding on neutrophils and monocytes from patients with head and neck cancer.

Authors:  R J Walter; J R Danielson
Journal:  J Natl Cancer Inst       Date:  1987-01       Impact factor: 13.506

9.  Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses.

Authors:  H Lapointe; H Lampe; D Banerjee
Journal:  Otolaryngol Head Neck Surg       Date:  1992-02       Impact factor: 3.497

10.  Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones.

Authors:  M P Tas; P J Simons; F J Balm; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.